© Website designed by Alasdair Coles, 2012
Current funders: Medical Research Council, Wellcome Trust, MS Society, Moulton Charitable Trust, Freemason’s Grand Charity. Clinical investigation of patients treated using alemtuzumab Orla Tuohy, Grant Cawthorne-Hill, Tom Button, with Michael Fahey [Australia] and David Miller [UCL] • We continue to follow up all patients treated using alemtuzumab, since 1991. We have recently published the follow-up of the people with progressive multiple sclerosis treated between 1991 and 1998. • We are now writing up the long-term follow-up of our relapsing-remitting cohort, treated since 1999. • We have just published a small study of MTR MRI imaging on people after alemtuzumab, showing recovery of MTR signal. • We have started a trial of a licensed drug (human KGF) to prevent autoimmunity after alemtuzumab. More information here.
Immunological studies of alemtuzumabJoanne Jones, Sara Thompson We are trying to answer three questions: Why do people get autoimmunnity after alemtuzumab? • Following on from Amanda Cox and Sara Thompson’s previous work, we have shown that the reconstitution of T lymphocytes occurs by expansion of peripheral T cells with reduced thymmic output. Can we predict who is at risk of autoimmunity after alemtuzumab? • Following Jo Jones’ initial description of the role of IL-21 in autoimmunity after alemtuzumab we are now refining this into a potential predictive biomarker for autoimmunity.
Reducing the immunogenicity of alemtuzumabAlasdair Coles, Jen Sommerfield with Herman Waldmann & Geoff Hale • People treated with alemtuzumab can develop antibodies to the drug which, rarely, can neutralise the efficacy of subsequent treatments. Following seminal work in Herman Waldmann’s lab, we performed a trial of pretreating patients with a variant of alemtuzumab designed to induce long-lasting tolerance to regular alemttuzumab.